Certified by Founder
Lodge
Arsenal Biosciences, Inc.
start up
United States
- South San Francisco , CA
- 04/09/2024
- Series C
- $325,000,000
ArsenalBiosciences, Inc., is a clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.
- Industry Biotechnology Research
- Website https://arsenalbio.com/
- LinkedIn https://www.linkedin.com/company/arsenalbio/
Iceotope | $26,000,000 | (May 15, 2026)
Harken Sweets | Undisclosed Amount | (May 15, 2026)
Graphon AI | $8,300,000 | (May 15, 2026)
Ranger AI | $8,400,000 | (May 15, 2026)
Wirestock | $23,000,000 | (May 15, 2026)
GridCARE | $64,000,000 | (May 15, 2026)
Chromie Health | $2,000,000 | (May 15, 2026)
Novella | $21,000,000 | (May 15, 2026)
Flick | $6,000,000 | (May 15, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)